Sign in Create account

Medico Remedies Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: MEDICO BSE: 540937
₹21.53
▼ -0.31 (-1.42%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
69/100
Moderate
Valuation
87/100
Undervalued
Momentum
5/100
Bearish

QVM read Cheap on its own multiples Quality Moderate, Valuation Undervalued, Momentum Bearish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹179 Cr
PE (TTM)
12.9
Industry median 36.1 (152 companies)
Price to Book
2.4
PEG (TTM)
0.4
Institutions holding %
Data unavailable.
Piotroski Score
7
Relative return vs Nifty50, qtr %
-31.7
Relative return vs Sector, qtr %
-45.5
Free Cash Flow
₹6 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
36.36%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-5.39%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
49.96%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
38.50%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
81.43%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.66
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.25
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
10.82
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
3.63%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
5.40%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
8.80%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
7.56%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
26.22%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
15.37%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

6 of 7 met
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Piotroski F-score is 7 or more (score 7)
  • Yes Debt to equity is below 0.5 (0.25)
  • Yes Return on equity is 15% or more (15.4%)
  • Yes Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

4 of 4 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)
  • Yes Insiders have not sold in the past 3 months (no open-market sale filed in the last 3 months)

Peer comparison

2 of 3 met
  • No 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

2 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Undervalued (below its own historical PE range))
  • Yes Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-1.4%
Low 21.1700 · High 23.6400
1W return
-34.1%
Low 20.4700 · High 33.2500
1M return
-49.2%
Low 20.4700 · High 43.0000
52W return
-55.4%
Low 20.4700 · High 56.8800
Lifetime High ₹387.0000 (March 13, 2023)
Lifetime Low ₹21.5300 (Sept. 30, 2026)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish0
Bearish6
5D
24.5
10D
28.1
20D
32.2
50D
37.2
100D
40.0
200D
43.1

Delivery and volume

Day avg. delivery
59.6%
Week avg. delivery
49.5%
Month avg. delivery
50.7%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

22.11
Pivot
First resistance23.06
Second resistance24.58
Third resistance25.53
First support20.59
Second support19.64
Third support18.12
Day RSI14.5
Day MFI22.3
Day MACD-4.67
Day MACD signal-3.26

Beta

1M1.00
3M1.90
1Y1.12
3Y0.64

Price change analysis

↓ -49.2%
Over 1 Month
LowHigh
20.4743.00
↓ -45.5%
Over 3 Months
LowHigh
20.4751.49
↓ -43.8%
Over 6 Months
LowHigh
20.4751.49
↓ -55.4%
Over 1 Year
LowHigh
20.4756.88
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 12.9 (own history: 20.6–55.4)
Undervalued (below its own historical PE range)

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹69 Cr
Net profit (June 30, 2026)
₹3 Cr
Basic EPS (June 30, 2026)
₹0.3000

Ranks #122 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter61.38%
  • FII/FPI0.08%

Largest holders

NameCategoryShares %Shares
HARESH KAPURLAL MEHTAPromoter20.2200%16779200
MEHTA RISHIT HARESHBHAIPromoter12.6500%10500000
HARSHIT HARESH MEHTAPromoter10.3900%8620000
RITA H MEHTAPromoter8.0500%6678000
RAVI GOYALPublic6.8300%5664309

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 61.38% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 0.03% to 0.08% in Jun 2026 qtr

Historical mutual fund holding

All shareholding details →

Insider trading, SAST & pledges

All 13 insider trades, 31 SAST, 0 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
26 Dec 2024 Shweta Harshit Mehta Promoter group Sell 0 ₹0
26 Dec 2024 Harshit H Mehta HUF Promoter Sell 0 ₹0
26 Dec 2024 Harshit H Mehta HUF Promoter Sell 0 ₹0
5 Dec 2024 Rishit Haresh Mehta Promoter group Sell 0 ₹0
5 Dec 2024 Rishit Haresh Mehta Promoter group Sell 0 ₹0
20 Nov 2024 Shweta Harshit Mehta Promoter group Sell 0 ₹0
20 Nov 2024 Harshit H Mehta HUF Promoter Sell 0 ₹0
20 Nov 2024 Rita Haresh Mehta Promoter Sell 0 ₹0
10 Jan 2024 Harshit Haresh Mehta Promoter Buy 0 ₹0
10 Jan 2024 Rishit Haresh Mehta Promoter group Buy 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 185 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
25 Sep 2026 SAVITRIBEN MAHENDRAKUMAR SHAH Bulk Sell 437,647 27.2200 NSE
25 Sep 2026 SAVITRIBEN MAHENDRAKUMAR SHAH Bulk Sell 437,647 27.2200 NSE
4 Aug 2026 L7 HITECH PRIVATE LIMITED Bulk Buy 430,000 48.3200 NSE
27 Mar 2026 RG HUF Bulk Sell 4,257,300 33.9300 NSE
27 Mar 2026 R G FAMILY TRUST Bulk Buy 4,257,300 33.9300 NSE
25 Mar 2026 RAVI GOYAL (HUF) Bulk Sell 1,400,000 37.6700 NSE
25 Mar 2026 R G FAMILY TRUST Bulk Buy 1,400,000 37.6700 NSE
23 Jan 2026 VISHAL MAHESH WAGHELA Bulk Buy 510,000 53.4100 NSE
23 Jan 2026 ALTIZEN VENTURES LLP Bulk Sell 706,950 52.6900 NSE
23 Jan 2026 ALTIZEN VENTURES LLP Bulk Buy 865,452 54.0000 NSE

All bulk and block deals →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
13 Aug 2026 Financial Results Yes
21 May 2026 Financial Results/Other business matters Yes
12 Feb 2026 Financial Results/Other business matters Yes
14 Nov 2025 Financial Results Yes
8 Aug 2025 Financial Results Yes

Corporate Announcements

All 3 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
29 Sep 2026 Insider Trading / SAST Medico Remedies Ltd - 540937 - Closure of Trading Window
29 Sep 2026 Company Update Medico Remedies Ltd - 540937 - Clarification On Price Movement
29 Sep 2026 Company Update Medico Remedies Ltd - 540937 - Clarification sought from Medico Remedies Ltd

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.25)
  • Comfortable interest coverage (10.8x)
  • Healthy liquidity (Current Ratio 1.66)
  • Strong revenue growth YoY (81.4%)

Weaknesses

  • Thin net profit margin (3.6%)

Opportunities

  • PEG below 1 (0.38) -- earnings growth outpacing its own valuation
  • PE below 15 (12.9) relative to a typical growth business
  • RSI in oversold territory (14.5) -- a technical rebound zone

Threats

  • Down 55.4% over the past year

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Medico Remedies Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.